Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT06511908 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

NIH

Sponsor class

Conditions

Suicide
Depressive Disorder, Treatment-Resistant
Ketamine
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Excitatory Amino Acid Agents
Physiological Effects of Drugs
Depressive Disorder, Major
Depressive Disorder
Depression
Mental Disorders
Mood Disorders
Behavioral Symptoms

Interventions

DRUG: (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
DRUG: Placebo

Sponsor

National Institute of Mental Health (NIMH)